Biogen Stock Surges 9.3%, With A 8-Day Winning Spree
Biogen (BIIB) – a biotechnology company developing therapies for neurological diseases – hit a 8-day winning streak, with cumulative gains over this period amounting to 9.3%. The company’s market cap has surged by about $2.6 Bil over the last 8 days and currently stands at $30 Bil.
Is this an opportunity or a trap? There is a near-equal mix of good and bad in BIIB stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell BIIB).
But here is the interesting part. You are reading about this 9.3% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
The following table summarizes the return for BIIB stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BIIB | S&P 500 |
|---|---|---|
| 1D | 2.6% | 0.6% |
| 8D (Current Streak) | 9.3% | 3.0% |
| 1M (21D) | 14.3% | 6.8% |
| 3M (63D) | 7.0% | 7.2% |
| YTD 2026 | 16.2% | 8.7% |
| 2025 | 15.1% | 16.4% |
| 2024 | -40.9% | 23.3% |
| 2023 | -6.6% | 24.2% |
However, big gains can follow sharp reversals – but how has BIIB behaved after prior drops? See BIIB Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 51 S&P constituents with 3 days or more of consecutive gains and 112 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 25 | 39 |
| 4D | 17 | 35 |
| 5D | 3 | 33 |
| 6D | 5 | 2 |
| 7D or more | 1 | 3 |
| Total >=3 D | 51 | 112 |
Key Financials for Biogen (BIIB)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $9.7 Bil | $9.9 Bil |
| Operating Income | $2.3 Bil | $2.5 Bil |
| Net Income | $1.6 Bil | $1.3 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $2.3 Bil | $2.5 Bil |
| Operating Income | $385.5 Mil | $459.8 Mil |
| Net Income | $-48.9 Mil | $319.5 Mil |
While BIIB stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.